Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zeposia (ozanimod)
Pharma
BMS wins FDA approval for new schizophrenia med Cobenfy
Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has borne fruit with the approval of a promising new schizophrenia drug.
Fraiser Kansteiner
Sep 26, 2024 7:38pm
Pfizer's Velsipity faces stiff competition in UC market: reports
Apr 4, 2024 12:14pm
BMS' Zeposia comes up short in Crohn's disease study
Mar 29, 2024 8:15am
Pfizer wins FDA approval to challenge BMS in ulcerative colitis
Oct 13, 2023 9:36am
BMS aims for staggering 25 label expansions in the coming years
Sep 15, 2023 12:04pm
BMS starts Women's World Cup ulcerative colitis marketing push
Jul 14, 2023 8:40am
